Literature DB >> 11696431

CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

C Trebst1, T L Sørensen, P Kivisäkk, M K Cathcart, J Hesselgesser, R Horuk, F Sellebjerg, H Lassmann, R M Ransohoff.   

Abstract

Mononuclear phagocytes (monocytes, macrophages, and microglia) are considered central to multiple sclerosis (MS) pathogenesis. Molecular cues that mediate mononuclear phagocyte accumulation and activation in the central nervous system (CNS) of MS patients may include chemokines RANTES/CCL5 and macrophage inflammatory protein-1alpha/CCL3. We analyzed expression of CCR1 and CCR5, the monocyte receptors for these chemokines, on circulating and cerebrospinal fluid CD14+ cells, and in MS brain lesions. Approximately 70% of cerebrospinal fluid monocytes were CCR1+/CCR5+, regardless of the presence of CNS pathology, compared to less than 20% of circulating monocytes. In active MS lesions CCR1+/CCR5+ monocytes were found in perivascular cell cuffs and at the demyelinating edges of evolving lesions. Mononuclear phagocytes in early demyelinating stages comprised CCR1+/CCR5+ hematogenous monocytes and CCR1-/CCR5- resident microglial cells. In later stages, phagocytic macrophages were uniformly CCR1-/CCR5+. Cultured in vitro, adherent monocytes/macrophages up-regulated CCR5 and down-regulated CCR1 expression, compared to freshly-isolated monocytes. Taken together, these findings suggest that monocytes competent to enter the CNS compartment derive from a minority CCR1+/CCR5+ population in the circulating pool. In the presence of ligand, these cells will be retained in the CNS. During further activation in lesions, infiltrating monocytes down-regulate CCR1 but not CCR5, whereas microglia up-regulate CCR5.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696431      PMCID: PMC1867058          DOI: 10.1016/s0002-9440(10)63017-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis.

Authors:  B Bonetti; C S Raine
Journal:  Ann Neurol       Date:  1997-07       Impact factor: 10.422

2.  Axonal damage in acute multiple sclerosis lesions.

Authors:  B Ferguson; M K Matyszak; M M Esiri; V H Perry
Journal:  Brain       Date:  1997-03       Impact factor: 13.501

3.  Activation of dual T cell signaling pathways by the chemokine RANTES.

Authors:  K B Bacon; B A Premack; P Gardner; T J Schall
Journal:  Science       Date:  1995-09-22       Impact factor: 47.728

4.  CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons.

Authors:  J Hesselgesser; M Halks-Miller; V DelVecchio; S C Peiper; J Hoxie; D L Kolson; D Taub; R Horuk
Journal:  Curr Biol       Date:  1997-02-01       Impact factor: 10.834

5.  Macrophages in multiple sclerosis.

Authors:  W Brück; N Sommermeier; M Bergmann; U Zettl; H H Goebel; H A Kretzschmar; H Lassmann
Journal:  Immunobiology       Date:  1996-10       Impact factor: 3.144

6.  MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation.

Authors:  W J Karpus; K J Kennedy
Journal:  J Leukoc Biol       Date:  1997-11       Impact factor: 4.962

7.  Oligodendrocytes in the early course of multiple sclerosis.

Authors:  W Brück; M Schmied; G Suchanek; Y Brück; H Breitschopf; S Poser; S Piddlesden; H Lassmann
Journal:  Ann Neurol       Date:  1994-01       Impact factor: 10.422

8.  Monocyte/macrophage differentiation in early multiple sclerosis lesions.

Authors:  W Brück; P Porada; S Poser; P Rieckmann; F Hanefeld; H A Kretzschmar; H Lassmann
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

9.  Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain.

Authors:  P Dowling; G Shang; S Raval; J Menonna; S Cook; W Husar
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

Review 10.  Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis.

Authors:  C F Lucchinetti; W Brück; M Rodriguez; H Lassmann
Journal:  Brain Pathol       Date:  1996-07       Impact factor: 6.508

View more
  75 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Authors:  Jessica E Taaffe; Steven E Bosinger; Gregory Q Del Prete; James G Else; Sarah Ratcliffe; Christopher D Ward; Thi Migone; Mirko Paiardini; Guido Silvestri
Journal:  J Med Primatol       Date:  2011-11-14       Impact factor: 0.667

3.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 4.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 5.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 6.  Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS.

Authors:  Benjamin D Clarkson; Erika Héninger; Melissa G Harris; JangEun Lee; Matyas Sandor; Zsuzsanna Fabry
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 7.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

8.  Haplotypes within genes of beta-chemokines in 17q11 are associated with multiple sclerosis: a second phase study.

Authors:  Tamara Vyshkina; Bernadette Kalman
Journal:  Hum Genet       Date:  2005-08-03       Impact factor: 4.132

Review 9.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

10.  Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.

Authors:  George P Christophi; Paul T Massa
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.